期刊文献+

Gleevec耐药白血病细胞中P-糖蛋白功能失调及其调节

P-glycoprotein Dysfunction and Modulation in Gleevec-resistant Leukemia Cells
下载PDF
导出
摘要 目的:明确Pgp在Gleevec耐药白血病细胞中的表达和功能,为临床合理用药提供理论指导。方法:四甲基偶氮唑盐(MTT)法检测K562/G01细胞对阿霉素(Doxorubicin,DOX)和伊马替尼(Gleevec,STI571)细胞毒作用的敏感性以及Pgp抑制剂维拉帕米(Verapamil,VPL)对K562/G01细胞药物敏感性的调节作用;RT-PCR和Western-blotting方法检测细胞中MDR基因mdr1及Pgp的表达;流式细胞仪(Flow cytometry,FCM)检测细胞内DOX及罗丹明123(Rhodamin123,Rho123)水平以及Gleevec和ATP对Pgp功能的调节作用。结果:人白血病Gleevec耐药K562/G01细胞对Gleevec耐药约40倍,但对MDR类化疗药物DOX却保持敏感,而且,Pgp抑制剂VPL不改变K562/G01细胞对DOX的敏感性。与MDR表型的K562/A02细胞一样,K562/G01细胞表达mdr1及其编码的Pgp蛋白,但Pgp却没有药物外排泵功能,K562/G01细胞中DOX或Rh123浓度与敏感细胞K562相当。加入Gleevec或ATP可明显降低K562/G01细胞中DOX水平。结论:人白血病Gleevec耐药细胞K562/G01表达mdr1/Pgp,但Pgp功能明显受阻,Bcr/Abl抑制剂Gleevec或ATP可部分恢复K562/G01细胞中Pgp的药物外排泵功能。 Objective:To assess the expression and function of P-glycoprotein(Pgp)in Gleevec-resistant leukemia cells.Methods:MTT assay was performed to evaluate the sensitivity of K562/G01 cells to doxorubicin(DOX)and Gleevec.The effect of verapamil(VPL)on the sensitivity of K562/G01 cells to drugs was also determined.RT-PCR and Western blotting were used to determine the expression of the multidrug resistance gene mdr1 and its protein product Pgp.Flow cytometry(FCM)was used to analyze intracellular levels of DOX and Rhodamine 123(Rho123),as well as the modulation of Pgp function by Gleevec and ATP.Results:Like K562/A02 MDR cells,K562/G01 cells expressed mdr1/Pgp.However,the drug efflux function of Pgp failed to be detected in K562/G01 cells.The intracellular concentrations of DOX and Rho123 were similar to those found in K562 cells.Adding either Gleevec or ATP to K562/G01 cells resulted in a markedly decreased level of intracellular DOX.Conclusion:Human leukemia Gleevec-resistant K562/G01 cells express dysfunctional mdr1/Pgp.The drug efflux pump activity of Pgp can be partially restored by adding Bcr/Abl inhibitor,Gleevec,or ATP.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2007年第17期973-977,共5页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金(编号:30572203) 天津市应用基础研究计划面上项目基金资助(编号:043610311)
关键词 白血病 Gleevec耐药性 P-糖蛋白 Leukemia Gleevec drug resistance P-glycoprotein
  • 相关文献

参考文献8

  • 1Ling V. Multidrug resistance: molecular mechanisms and clinical relevance [[]. Cancer Chemother Pharmacol, 1997, 40 (Suppl): S3-S8
  • 2Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance[J]. Blood, 2000, 96(3): 1070-1079
  • 3Illmer T,Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate[J]. Leukemia, 2004, 18(3): 401-408
  • 4Rumpold H, Wolf AM, Gruenewald K, et al. RNAi--mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines[J]. Exp Hematol, 2005, 33(7): 767-775
  • 5Ferrao PT, Frost MJ, Siah SP, et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro [J]. Blood, 2003, 102(13): 4499-4503
  • 6齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 7Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models[J]. Blood, 2003, 101(6): 2368-2373
  • 8Versantvoort CH, Broxterman HJ, Lankelma J, et al. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell hmg cancer cells[J]. Biochem Pharmacol, 1994, 48(6): 1129 -1136

二级参考文献15

  • 1Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 1996,2:561-566.
  • 2Gambacorti-Passenini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mos Dis, 1997,23:380-394.
  • 3Corrol M, Ohno-Jones S, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood,1997,90:4947-4952.
  • 4Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood,1997,90:3691-3698.
  • 5Gorre ME, Mahammed M, Ellwod K ,et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Blood,2001,293:876-880.
  • 6Tipping AJ, Mahon FX, Lagarde V, et al. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood,2001,98:3864-3867.
  • 7Yang CZ, Luan FJ,Xiong DS,et al. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicine. Acta Pharmacologica Sinica, 1995,16: 333-337.
  • 8Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983,65: 55-63.
  • 9Gorre ME,Mahammed M,Ellwod K,et al.Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification.Blood,2001,93:876-880.
  • 10Noonan KE,Beck C,Holzmayer TA,et al.Quantitation analysis of MDR1(multidrug resistance) gene expression in human tumor by polymerase chain reaction.Proc Natl Acad Sci U S A,1990,87:7160-7168.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部